Brief: Ortho Regenerative Technologies Selects Us Based Specialized CRO, MCRA LLC, For Its Upcoming Phase I/II Rotator Cuff Human Trial
12/09/2019 12:13
Sept 12 (Reuters) - Ortho Regenerative Technologies Inc
ORTH.CD :
* ORTHO REGENERATIVE TECHNOLOGIES SELECTS US BASED
SPECIALIZED
CRO, MCRA LLC, FOR ITS UPCOMING PHASE I/II ROTATOR CUFF HUMAN
TRIAL
* ORTHO REGENERATIVE TECHNOLOGIES - ORTHO-R PHASE I/II
CLINICAL
TRIAL PLANS TO ENROLL 75 PATIENTS, RANDOMIZED ACROSS 3 ARMS OF
25 PATIENTS IN U.S.
Source text for Eikon: ID:nCNWMFrMqa
Further company coverage: ORTH.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chitogenx
See all newsBrief: Chitogenx Announces Signing Of Binding Letter Of Intent With Oligo Medic
Brief: Chitogenx Announces Executive Leadership Changes
Brief: Chitogenx Inc - Study Results To Be Available Q3-24 After Mandatory Post-Surgery Monitoring
Brief: Chitogenx Concludes Enrolment For Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial
Brief: Chitogenx Announces New $2.5 Million Non-Brokered Private Placement Offering And Balance Sheet Restructuring